PP2A mediates diosmin p53 activation to block HA22T cell proliferation and tumor growth in xenografted nude mice through PI3K-Akt-MDM2 signaling suppression

Food and Chemical Toxicology

Volumn 50, Issue 5, 2012, Pages 1802-1810

  Dung, Tran Duc ^a,c   Day, Cecilia Hsuan ^b   Binh, Truong Viet ^c   Lin, Chih Hsueh ^a   Hsu, Hsi Hsien ^d   Su, Cheng Chuan ^e   Lin, Yueh Min ^f   Tsai, Fuu Jen ^a   Kuo, Wei Wen ^a   Chen, Li Mien ^g,h   Huang, Chih Yang ^a,i  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

^c Vietnam University of Traditional Pharmaco Medicine   (Viet Nam)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^f CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^g Taichung General Hospital   (Taiwan)

^h CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

ⁱ ASIA UNIVERSITY   (Taiwan)

Author keywords

Cell proliferation; Diosmin; Hepatocellular carcinoma; Nude mice model; Protein phosphatase 2A

Indexed keywords

DIOSMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN HA22T; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL PROLIFERATION; DIOSMIN; FLOW CYTOMETRY; HEPATOCYTES; MALE; MICE; MICE, NUDE; OKADAIC ACID; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

MUS MUSCULUS;

EID: 84859364854     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.01.021     Document Type: Article

References (38)

1. Bell H.S., Ryan K.M. Targeting the p53 family for cancer therapy: 'big brother' joins the fight. Cell. Cycle 2007, 6:1995-2000.
2. Berry M.N., Friend D.S. High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J. Cell Biol. 1969, 43:506-520.
3. Bonney R.J., Becker J.E., Walker P.R., Potter V.R. Primary monolayer cultures of adult rat liver parenchymal cells suitable for study of the regulation of enzyme synthesis. In Vitro 1974, 9:399-413.
4. Brooks C.L., Gu W. P53 ubiquitination: MDM2 and beyond. Mol. Cell 2006, 21:307-315.
5. Chang K.T., Lii C.K., Tsai C.W., Yang A.J., Chen H.W. Modulation of the expression of the pi class of glutathione S-transferase by Andrographis paniculata extracts and andrographolide. Food. Chem. Toxicol. 2008, 46:1079-1088.
6. Chen K.F., Yu H.C., Liu T.H., Lee S.S., Chen P.J., Cheng A.L. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J. Hepatol. 2010, 52:88-95.
7. Cohen P. Classification of protein-serine/threonine phosphatases: identification and quantitation in cell extracts. Methods. Enzymol. 1991, 201:389-398.
8. Cohen P., Holmes C.F., Tsukitani Y. Okadaic acid: a new probe for the study of cellular regulation. Trends. Biochem. Sci. 1990, 15:98-102.
9. Deane N.G., Parker M.A., Aramandla R., Diehl L., Lee W.J., Washington M.K., Nanney L.B., Shyr Y., Beauchamp R.D. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer. Res. 2001, 61:5389-5395.
10. Doskeland A.P., Vintermyr O.K., Flatmark T., Cotton R.G., Doskeland S.O. Phenylalanine positively modulates the cAMP-dependent phosphorylation and negatively modulates the vasopressin-induced and okadaic-acid-induced phosphorylation of phenylalanine 4-monooxygenase in intact rat hepatocytes. Eur. J. Biochem. 1992, 206:161-170.
11. El-Shafae A.M., El-Domiaty M.M. Improved LC methods for the determination of diosmin and/or hesperidin in plant extracts and pharmaceutical formulations. J. Pharm. Biomed. Anal. 2001, 26:539-545.
12. Erster S., Mihara M., Kim R.H., Petrenko O., Moll U.M. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol. Cell. Biol. 2004, 24:6728-6741.
13. Giono L.E., Manfredi J.J. The p53 tumour suppressor participates in multiple cell cycle checkpoints. J. Cell. Physiol. 2006, 209:13-20.
14. Gomaa A.I., Khan S.A., Toledano M.B., Waked I., Taylor-Robinson S.D. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 2008, 14:4300-4308.
15. Gordan J.D., Thompson C.B., Simon M.C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer. Cell 2007, 12:108-113.
16. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer. Res. 1994, 54:4855-4878.
17. Hart M.E., Chamberlin A.R., Walkom C., Sakoff J.A., McCluskey A. Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg. Chem. Bioorg. Chem. 2004, 14:1969-1973.
18. Hitzenberger G. Therapeutic effectiveness of flavonoids illustrated by daflon 500mg. Wien. Med. Wochenschr. 1997, 147:409-412.
19. Honkanen R.E. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett. 1993, 330:283-286.
20. Inoue T., Geyer R.K., Yu Z.K., Maki C.G. Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett. 2001, 490:196-201.
21. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
22. Kim S.W., Kim H.J., Chun Y.J., Kim M.Y. Ceramide produces apoptosis through induction of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. J. Toxicol. Environ. Health A 2010, 73:1465-1476.
23. Kinoshita N., Ohkura H., Yanagida M. Distinct, essential roles of type 1 and 2A protein phosphatases in the control of the fission yeast cell division cycle. Cell 1990, 63:405-415.
24. Lee Y.M., Wu T.H., Chen S.F., Chung J.G. Effect of 5-methoxypsoralen (5-MOP) on cell apoptosis and cell cycle in human hepatocellular carcinoma cell line. Toxicol. In Vitro 2003, 17:279-287.
25. Li M., Brooks C.L., Wu-Baer F., Chen D., Baer R., Gu W. Mono- versus polyubiquitination: differential control of p53 fate by MDM2. Science 2003, 302:1972-1975.
26. Liu W., Huang X.F., Qi Q., Dai Q.S., Yang L., Nie F.F., Lu N., Gong D.D., Kong L.Y., Guo Q.L. Asparanin A induces G(2)/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Biochem. Biophys. Res. Commun. 2009, 381:700-705.
27. Lonchampt M., Guardiola B., Sicot N., Bertrand M., Perdrix L., Duhault J. Protective effect of a purified flavonoid fraction against reactive oxygen radicals. In vivo and in vitro study. Arzneimittelforschung 1989, 39:882-885.
28. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 2009, 9:153-166.
29. Manchado E., Guillamot M., de Carcer G., Eguren M., Trickey M., Garcia-Higuera I., Moreno S., Yamano H., Canamero M., Malumbres M. Targeting mitotic exit leads to tumour regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55alpha, delta phosphatase. Cancer Cell 2010, 18:641-654.
30. Neviani P., Santhanam R., Trotta R., Notari M., Blaser B.W., Liu S., Mao H., Chang J.S., Galietta A., Uttam A., Roy D.C., Valtieri M., Bruner-Klisovic R., Caligiuri M.A., Bloomfield C.D., Marcucci G., Perrotti D. The tumour suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8:355-368.
31. Pari L., Srinivasan S. Antihyperglycemic effect of diosmin on hepatic key enzymes of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Biomed. Pharmacother. 2010, 64:477-481.
32. Roger L., Gadea G., Roux P. Control of cell migration: a tumour suppressor function for p53?. Biol. Cell. 2006, 98:141-152.
33. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
34. Tanaka T., Makita H., Kawabata K., Mori H., Kakumoto M., Satoh K., Hara A., Sumida T., Ogawa H. Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis 1997, 18:957-965.
35. Wang Z., Wang M., Kar S., Carr B.I. Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition. J. Cell. Physiol. 2009, 221:213-220.
36. Wu W.Y., Xu Q., Shi L.C., Zhang W.B. Inhibitory effects of Curcuma aromatica oil on proliferation of hepatoma in mice. World J. Gastroenterol. 2000, 6:216-219.
37. Yang M., Tanaka T., Hirose Y., Deguchi T., Mori H., Kawada Y. Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice. Int. J. Cancer 1997, 73:719-724.
38. Yoo H.H., Lee M., Chung H.J., Lee S.K., Kim D.H. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J. Agric. Food. Chem. 2007, 55:7620-7625.